TPA (12-0-tetradecanoylphorbol-13-acetate), a potent tumor pro moter, has been shown to stimulate or inhibit cell growth depending on the cell type investigated. We recently found that RT101 cells, a trans formed mouse JB6 epidermal cell line, acquired a greater growth inhibi tion response to TPA during conventional subcultivation. The growth of low-passage RT101 cells was slightly inhibited by...

BACKGROUND AND PURPOSE Stroke mimics (SM) challenge the initial assessment of patients presenting with possible acute ischemic stroke (AIS). When SM is considered likely, intravenous tissue-type plasminogen activator (tPA) may be withheld, risking an opportunity to treat AIS. Although computed tomography is routinely used for tPA decision making, magnetic resonance imaging (MRI) may diagnose AI...

BACKGROUND Substantial efforts over the past decade have increased rates of intravenous tissue plasminogen activator (tPA) use in the United States. We sought to determine changes in patient characteristics and rates of tPA use over time among hospitalized acute ischemic stroke (AIS) patients. METHODS AND RESULTS We analyzed all AIS patients (n=1 093 895) and those arriving ≤ 2 hours and trea...

To further improve fertility of animals, a novel gene RFRP-3 (RF-amide related peptide-3, RFRP-3) was used to construct DNA vaccines with INH α (1-32) (inhibin, INH) fragment for the first time. The aim of this study was to evaluate the effects of novel DNA vaccines on fertility in mice. Synthesized SINH and SRFRP (INH and RFRP genes were separately ligated to the C-terminus of the small envelo...

We recently discovered that patients with essential hypertension have a markedly impaired capacity for stimulated release of tissue plasminogen activator (tPA) from vascular endothelium. This defect may reduce the chance of timely spontaneous thrombolysis in case of an atherothrombotic event. We now investigated whether increased intraluminal pressure as such may depress vascular tPA release or...

Significant shortcomings in clinical thrombolysis efficiencies and arterial recanalization rates still exist to date necessitating the development of additional thrombolysis-enhancing technologies. For example, to improve tPA-induced systemic clot lysis several supplementary treatment methods have been proposed, among them ultrasound-enhanced tissue plasminogen activator (tPA) thrombolysis whic...

BACKGROUND AND PURPOSE Thrombolytic therapy with tissue plasminogen activator (tPA) in ischemic stroke is limited by increased risks of cerebral hemorrhage and brain injury. In part, these phenomena may be related to neurovascular proteolysis mediated by matrix metalloproteinases (MMPs). Here, we used a combination of pharmacological and genetic approaches to show that tPA promotes MMP-9 levels...

Abstract 3D printing in the textile and fashion industry is a new emerging technology. Applications of for designing clothes other wearable accessories require tribological biological understanding plastics against complex human skin to mitigate skin-friction related ailments such as calluses blisters. This study provides insight search an optimal printable material that has minimal friction sk...

Risk of hemorrhagic transformation, incomplete reperfusion, neurotoxicity, and a short treatment time window comprises major challenges for tissue plasminogen activator (tPA) thrombolytic stroke therapy. Improving tPA therapy has become one of the highest priorities in the stroke field. This mini review article focuses on our recent efforts aimed at evaluating a novel combination approach of lo...

We report on two-photon absorption ~TPA! photocurrent in semiconductor microcavities. We experimentally show a substantial increase in the TPA photocurrent generated, at resonance, in a GaAlAs/GaAs microcavity designed for TPA operation at ;890 nm. An enhancement factor of ;12 000 of the photocurrent is obtained via the microcavity effect, which could have an important impact on the use of TPA ...